Top

Published in:

Open Access 01-12-2021 | Laryngeal Cancer | Research article

TINCR inhibits the proliferation and invasion of laryngeal squamous cell carcinoma by regulating miR-210/BTG2

Authors: Guoqing He, Rui Pang, Jihua Han, Jinliang Jia, Zhaoming Ding, Wen Bi, Jiawei Yu, Lili Chen, Jiewu Zhang, Yanan Sun

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Terminal differentiation-induced ncRNA (TINCR) plays an essential role in epidermal differentiation and is involved in the development of various cancers.

Methods

qPCR was used to detect the expression level of TINCR in tissues and cell lines of laryngeal squamous cell carcinoma (LSCC). The potential targets of TINCR were predicted by the bioinformation website. The expression of miR-210 and BTG2 genes were detected by qPCR, and the protein levels of BTG2 and Ki-67 were evaluated by western blot. CCK-8 assay, scratch test, and transwell chamber were used to evaluate the proliferation, invasion, and metastasis ability of LSCC cells. The relationships among TINCR, miR-210, and BTG2 were investigated by bioinformatics software and luciferase reporter assay. The in vivo function of TINCR was accessed on survival rate and tumor growth in nude mice.

Results

We used qRT-PCR to detect the expression of TINCR in laryngeal squamous cell carcinoma (LSCC) tissues and cells and found significantly lower levels in cancer tissues compared with adjacent tissues. Additionally, patients with high TINCR expression had a better prognosis. TINCR overexpression was observed to inhibit the proliferation and invasion of LSCC cells. TINCR was shown to exert its antiproliferation and invasion effects by adsorbing miR-210, which significantly promoted the proliferation and invasion of laryngeal squamous cells. Overexpression of miR-210 was determined to reverse the tumour-suppressive effects of TINCR. BTG2 (anti-proliferation factor 2) was identified as the target gene of miR-210, and BTG2 overexpression inhibited the proliferation and invasion of LSCC cells. BTG2 knockdown relieved the inhibitory effects of TINCR on the proliferation and invasion of LSCC. Finally, TINCR upregulation slowed xenograft tumour growth in nude mice and significantly increased survival compared with control mice.

Conclusion

The results of this study suggest that TINCR inhibits the proliferation and invasion of LSCC by regulating the miR-210/BTG2 pathway, participates in cell cycle regulation, and may become a target for the treatment of LSCC.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRef

Cossu AM, Mosca L, Zappavigna S, Misso G, Bocchetti M, De Micco F, et al. Long non-coding RNAs as important biomarkers in laryngeal Cancer and other head and neck Tumours. Int J Mol Sci. 2019;20(14). https://doi.org/10.3390/ijms20143444.

Cui X, Yu T, Shang J, Xiao D, Wang X. Long non-coding RNA CDKN2B-AS1 facilitates laryngeal squamous cell Cancer through regulating miR-497/CDK6 pathway. Onco Targets Ther. 2019;12:8853–62. https://doi.org/10.2147/OTT.S221620.CrossRefPubMedPubMedCentral

Zhang S, Ma H, Zhang D, Xie S, Wang W, Li Q, et al. LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling. Cell Death Dis. 2018;9(7):742. https://doi.org/10.1038/s41419-018-0793-5.CrossRefPubMedPubMedCentral

Zhu M, Zhang C, Chen D, Chen S, Zheng H. lncRNA MALAT1 potentiates the progression of tongue squamous cell carcinoma through regulating miR-140-5p-PAK1 pathway. Onco Targets Ther. 2019;12:1365–77. https://doi.org/10.2147/OTT.S192069.CrossRefPubMedPubMedCentral

Qu L, Jin M, Yang L, Sun C, Wang P, Li Y, et al. Expression of long non-coding RNA HOXA11-AS is correlated with progression of laryngeal squamous cell carcinoma. Am J Transl Res. 2018;10(2):573–80.PubMedPubMedCentral

Kretz M, Siprashvili Z, Chu C, Webster DE, Zehnder A, Qu K, et al. Control of somatic tissue differentiation by the long non-coding RNA TINCR. Nature. 2013;493(7431):231–5. https://doi.org/10.1038/nature11661.CrossRef

Zhang ZY, Lu YX, Zhang ZY, Chang YY, Zheng L, Yuan L, et al. Loss of TINCR expression promotes proliferation, metastasis through activating EpCAM cleavage in colorectal cancer. Oncotarget. 2016;7(16):22639–49. https://doi.org/10.18632/oncotarget.8141.CrossRefPubMedPubMedCentral

Xu Y, Qiu M, Chen Y, Wang J, Xia W, Mao Q, et al. Long noncoding RNA, tissue differentiation-inducing nonprotein coding RNA is upregulated and promotes development of esophageal squamous cell carcinoma. Dis Esophagus. 2016;29(8):950–8. https://doi.org/10.1111/dote.12436.CrossRefPubMed

10.

Schanen BC, Li X. Transcriptional regulation of mammalian miRNA genes. Genomics. 2011;97(1):1–6. https://doi.org/10.1016/j.ygeno.2010.10.005.CrossRefPubMed

11.

Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12. https://doi.org/10.1016/j.ydbio.2006.08.028.CrossRefPubMed

12.

Tian L, Cao J, Jiao H, Zhang J, Ren X, Liu X, et al. CircRASSF2 promotes laryngeal squamous cell carcinoma progression by regulating the miR-302b-3p/IGF-1R axis. Clin Sci (Lond). 2019;133(9):1053–66. https://doi.org/10.1042/CS20190110.CrossRef

13.

Chen Y, Guo Y, Yan W. lncRNA RP5-916L7.2 correlates with advanced tumor stage, and promotes cells proliferation while inhibits cells apoptosis through targeting miR-328 and miR-939 in tongue squamous cell carcinoma. Clin Biochem. 2019;67:24–32. https://doi.org/10.1016/j.clinbiochem.2019.02.013.CrossRefPubMed

14.

Zheng X, Zhao K, Liu T, Liu L, Zhou C, Xu M. Long noncoding RNA PVT1 promotes laryngeal squamous cell carcinoma development by acting as a molecular sponge to regulate miR-519d-3p. J Cell Biochem. 2019;120(3):3911–21. https://doi.org/10.1002/jcb.27673.CrossRefPubMed

15.

Xu CZ, Jiang C, Wu Q, Liu L, Yan X, Shi R. A feed-forward regulatory loop between HuR and the long noncoding RNA HOTAIR promotes head and neck squamous cell carcinoma progression and metastasis. Cell Physiol Biochem. 2016;40(5):1039–51. https://doi.org/10.1159/000453160.CrossRefPubMed

16.

Sarkar D, Leung EY, Baguley BC, Finlay GJ, Askarian-Amiri ME. Epigenetic regulation in human melanoma: past and future. Epigenetics. 2015;10(2):103–21. https://doi.org/10.1080/15592294.2014.1003746.CrossRefPubMedPubMedCentral

17.

Hazawa M, Lin DC, Handral H, Xu L, Chen Y, Jiang YY, et al. ZNF750 is a lineage-specific tumour suppressor in squamous cell carcinoma. Oncogene. 2017;36(16):2243–54. https://doi.org/10.1038/onc.2016.377.CrossRefPubMed

18.

Cao YP, Zhou J, Li WJ, Shao Y, Zheng SY, Tian T, et al. Long non-coding RNA expression profiles for the characterization of different bladder Cancer grade. Cell Physiol Biochem. 2018;50(3):1154–63. https://doi.org/10.1159/000494542.CrossRefPubMed

19.

Wang Y, Du L, Yang X, Li J, Li P, Zhao Y, et al. A nomogram combining long non-coding RNA expression profiles and clinical factors predicts survival in patients with bladder cancer. Aging (Albany NY). 2020;12(3):2857–79. https://doi.org/10.18632/aging.102782.CrossRefPubMedCentral

20.

Chen Z, Liu Y, He A, Li J, Chen M, Zhan Y, et al. Theophylline controllable RNAi-based genetic switches regulate expression of lncRNA TINCR and malignant phenotypes in bladder cancer cells. Sci Rep. 2016;6(1):30798. https://doi.org/10.1038/srep30798.CrossRefPubMedPubMedCentral

21.

Xu G, Yang H, Liu M, Niu J, Chen W, Tan X, et al. lncRNA TINCR facilities bladder cancer progression via regulating miR-7 and mTOR. Mol Med Rep. 2020;22:4243–53.PubMedPubMedCentral

22.

Sáenz-de-Santa-María I, Bernardo-Castiñeira C, Secades P, Bernaldo-de-Quirós S, Rodrigo JP, Astudillo A, et al. Clinically relevant HIF-1α-dependent metabolic reprogramming in oropharyngeal squamous cell carcinomas includes coordinated activation of CAIX and the miR-210/ISCU signaling axis, but not MCT1 and MCT4 upregulation. Oncotarget. 2017;8(8):13730–46. https://doi.org/10.18632/oncotarget.14629.CrossRefPubMedPubMedCentral

23.

Liu Y, Ye F. Construction and integrated analysis of crosstalking ceRNAs networks in laryngeal squamous cell carcinoma. PeerJ. 2019;7:e7380. https://doi.org/10.7717/peerj.7380.CrossRefPubMedPubMedCentral

24.

Zuo J, Wen M, Lei M, Peng X, Yang X, Liu Z. MiR-210 links hypoxia with cell proliferation regulation in human Laryngocarcinoma cancer. J Cell Biochem. 2015;116(6):1039–49. https://doi.org/10.1002/jcb.25059.CrossRefPubMed

25.

Liu X, Ma J, Xu F, Li L. TINCR suppresses proliferation and invasion through regulating miR-544a/FBXW7 axis in lung cancer. Biomed Pharmacother. 2018;99:9–17. https://doi.org/10.1016/j.biopha.2018.01.049.CrossRefPubMed

26.

Chen Z, Liu H, Yang H, Gao Y, Zhang G, Hu J. The long noncoding RNA, TINCR, functions as a competing endogenous RNA to regulate PDK1 expression by sponging miR-375 in gastric cancer. Onco Targets Ther. 2017;10:3353–62. https://doi.org/10.2147/OTT.S137726.CrossRefPubMedPubMedCentral

27.

Zhang X, Yao J, Shi H, Gao B, Zhang L. LncRNA TINCR/microRNA-107/CD36 regulates cell proliferation and apoptosis in colorectal cancer via PPAR signaling pathway based on bioinformatics analysis. Biol Chem. 2019;400(5):663–75. https://doi.org/10.1515/hsz-2018-0236.CrossRefPubMed

28.

Li T, Mo X, Fu L, Xiao B, Guo J. Molecular mechanisms of long noncoding RNAs on gastric cancer. Oncotarget. 2016;7(8):8601–12. https://doi.org/10.18632/oncotarget.6926.CrossRefPubMedPubMedCentral

29.

Lim IK. TIS21 (/BTG2/PC3) as a link between ageing and cancer: cell cycle regulator and endogenous cell death molecule. J Cancer Res Clin Oncol. 2006;132(7):417–26. https://doi.org/10.1007/s00432-006-0080-1.CrossRefPubMed

30.

Mao B, Zhang Z, Wang G. BTG2: a rising star of tumor suppressors (review). Int J Oncol. 2015;46(2):459–64. https://doi.org/10.3892/ijo.2014.2765.CrossRefPubMed

31.

Guéhenneux F, Duret L, Callanan MB, Bouhas R, Hayette S, Berthet C, et al. Cloning of the mouse BTG3 gene and definition of a new gene family (the BTG family) involved in the negative control of the cell cycle. Leukemia. 1997;11(3):370–5. https://doi.org/10.1038/sj.leu.2400599.CrossRefPubMed

32.

Winkler GS. The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol. 2010;222(1):66–72. https://doi.org/10.1002/jcp.21919.CrossRefPubMed

33.

Xie Y, Du J, Liu Z, Zhang D, Yao X, Yang Y. MiR-6875-3p promotes the proliferation, invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway. J Exp Clin Cancer Res. 2019;38(1):7. https://doi.org/10.1186/s13046-018-1020-z.CrossRefPubMedPubMedCentral

34.

Liu M, Wu H, Liu T, Li Y, Wang F, Wan H, et al. Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res. 2009;19(7):828–37. https://doi.org/10.1038/cr.2009.72.CrossRefPubMed

Title: TINCR inhibits the proliferation and invasion of laryngeal squamous cell carcinoma by regulating miR-210/BTG2
Authors: Guoqing He
Rui Pang
Jihua Han
Jinliang Jia
Zhaoming Ding
Wen Bi
Jiawei Yu
Lili Chen
Jiewu Zhang
Yanan Sun
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Laryngeal Cancer
Laryngeal Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08513-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Association between heavy metals and colon cancer: an ecological study based on geographical information systems in North-Eastern Iran

AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer

Integrated bioinformatic analysis identifies UBE2Q1 as a potential prognostic marker for high grade serous ovarian cancer

Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells

Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study

Extending screening intervals for women at low risk of breast cancer: do they find it acceptable?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer